Title |
Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease
|
---|---|
Published in |
Cochrane database of systematic reviews, November 2013
|
DOI | 10.1002/14651858.cd002309.pub4 |
Pubmed ID | |
Authors |
Chong, Jimmy, Leung, Bonnie, Poole, Phillippa |
Abstract |
Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea and a reduction in lung function, quality of life and life expectancy. Apart from smoking cessation, there are no other treatments that slow lung function decline. Roflumilast and cilomilast are oral phosphodiesterase 4 (PDE4) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD. |
Twitter Demographics
The data shown below were collected from the profiles of 12 tweeters who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 3 | 25% |
Indonesia | 1 | 8% |
Spain | 1 | 8% |
Unknown | 7 | 58% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 9 | 75% |
Science communicators (journalists, bloggers, editors) | 1 | 8% |
Practitioners (doctors, other healthcare professionals) | 1 | 8% |
Scientists | 1 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 167 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 1% |
United States | 1 | <1% |
Italy | 1 | <1% |
Unknown | 163 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 38 | 23% |
Researcher | 27 | 16% |
Student > Postgraduate | 14 | 8% |
Student > Bachelor | 14 | 8% |
Other | 12 | 7% |
Other | 29 | 17% |
Unknown | 33 | 20% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 58 | 35% |
Psychology | 22 | 13% |
Nursing and Health Professions | 11 | 7% |
Social Sciences | 10 | 6% |
Engineering | 4 | 2% |
Other | 16 | 10% |
Unknown | 46 | 28% |